A brief developed by Hepatitis Australia, with support from Gilead and GSK, highlights the progress made to date toward eliminating hepatitis B and hepatitis C in Australia. It explores remaining challenges and outlines the broader human, social, and economic impacts of not meeting the 2030 elimination targets.
This brief is intended as a conversation starter ahead of a forthcoming, detailed report that will combine economic modelling with lived experience insights to demonstrate the full value of achieving hepatitis B and hepatitis C elimination in Australia.
